Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New sedative ciprofol aims to cut heart injury after lung surgery

NCT ID NCT07028593

Disease control Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether ciprofol, a newer sedative, can reduce heart injury after lung surgery compared to the standard drug propofol. About 1,058 adults aged 45–80 having video-assisted lung surgery will be randomly assigned to receive one of the two drugs during anesthesia. The main goal is to see if ciprofol lowers the rate of heart muscle damage in the days after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ciprofol (also known as HSK3486)
What this could lead to
If ciprofol works better than propofol, it could become a safer sedative for surgery, lowering the risk of heart damage after lung operations.
What could go wrong
This is a Phase 4 trial, but it only looks at one type of surgery and one complication. Results may not apply to other surgeries or patients, and ciprofol might not prove superior.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 1,058 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Scheduled for elective video-assisted thoracoscopic (VATS)-assisted thoracic surgery (lobectomy, segmentectomy, wedge resection of two or more lung tissues, mediastinal tumor resection) under general anesthesia; 2. Aged 45 to 80 years (inclusive) at the time of randomization; 3. Expected postoperative hospital stay of ≥3 days; 4. Signed a written informed consent to participate in the study. Exclusion Criteria: 1. Patients allergic to propofol, Ciprofol, or analogs of drug excipient components (soybeans, eggs, milk); 2. Patients with unstable angina; 3. Patients with congestive heart failure or hemodynamic instability requiring vasopressor agents; 4. Patients with severe COPD (FEV1 \< 1 L); 5. Glomerular filtration rate \[eGFR\] \< 30 mL/min/1.73m²; 6. Patients with severe hepatic dysfunction (ALT or AST elevation exceeding 1.5 times the upper limit of normal); 7. Male or female patients planning to conceive within the next 3 months; 8. Pregnant or lactating female patients;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm mediastinal cancer Thoracic Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myocardial injury Thoracic diseases Thoracoscopic surgery

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tongji hospital

    RECRUITING

    Wuhan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.